AMD/ANTI-ANGIOGENESIS

• Correlation of Optical Coherence Tomography and Retinal Angiography in Patients Treated with Bevacizumab for CNV Membrane Swati Agarwal, MD
• Macrophages inhibit neovascularization in a murine model of ARMD Rajendra S. Apte, MD, PhD
• Triple Combination Therapy (PDT with Intravitreal Bevacizumab and Subtenon Triamcinolone Acetonide) for CNV Alay S. Banker, MD
• Vision Improvement with Combination Low-Fluence Photodynamic Therapy (LFPDT) and Intravitreal Injection Gregory R. Blaha, MD, PhD
• Survey of Current and Future Avastin Usage: Emphasis on Economics Gregory R. Blaha, MD, PhD
• PDT for Subfoveal Predominantly Hemorrhagic CNV Lesion Secondary to ARMD Francesco Boscia, MD
• Evaluation of Relationship between VEGF levels and ARMD K. V. Chalam, MD, PhD
• Retinal Pigment Epithelial Tears after Intraocular Bevacizumab (Avastintm) Injection for Neovascular ARMD Clement K. Chan, MD
• Use of Double Reciprocal Analysis to Compare Pharmacological Treatments for Subfoveal Exudative ARMD Lucian V. Del Priore, MD, PhD
• Comparison of PDT Combined With Immediate Versus Delayed IVT Acetonide for CNV Ajay Dudani, MD
• Age Influence on the Results of PDT of Subfoveal or Juxtafoveal CNV in Pathologic Myopia Leila El Matri, MD
• Subretinal Surgery with the Combination RPE and Choroidal Transplantation for the Treatment of ARMD Related Visual Loss in a US Management Algorithm Calvin A. Grant, MD
• Sequential Pegaptanib Monotherapy following Verteporfin PDT for CNV Paul B. Griggs, MD
• Expression of VEGF and Endostatin in Human CNV Membranes following Verteporfin PDT Salvatore Grisanti, MD
• Comparison between IVT and Bevacizumab for Serous PED and Occult CNV Secondary to ARMD David Hauser, MD
• Combination Pegaptanib and PDT for Subfoveal CNV Secondary to ARMD ThucAnh Thi Ho, MD
• VeriTAS: Study Design and Baseline Characteristics for a Combination Therapy Trial in Wet ARMD Peter K. Kaiser, MD
• Combined PDT and IVT Injection for the Treatment of Subfoveal CNV Noha Khater
• Clinical Characteristics of Exudative ARMD in Asian Patients Gregg T. Kokame, MD
• Vascular Leakage as a Predictive Factor of Outcome of PDT with Visudyne® Jaco Lavinsky, MD
• Outcomes of PDT for idiopathic Polypoidal Choroidal Vasculopathy Mun-Wai Lee, MD
• Multifocal electroretinographic long-term follow up in 12 cases of minimally classic or occult SRNV in ARMD treated with Pegaptanib sodium (Macugen) Andreas Lipski, MD
• Clinical course of massive submacular hemorrhage: a Hong Kong perspective David TL Liu, MD
• New Progress in the Surgical Treatment of ARMD by Vortex Vein Occlusion Richard Luscan, MD
• Visual Outcome of Intravitreal Bevacizumab for Neovascular ARMD Charles E. Lyon, MD
• Combined Intravitreal Avastin with Phacoemulsification in Visually Significant Cataract and Visually Significant Maculopathy Ahmad M. Mansour, MD
• Treatment of neovascular ARMD with Intravitreal Bevacizumab (Avastin®): efficacy of 3 consecutive monthly injections Alex Melamud, MD
• Systemic Avastin Therapy for Neovascular ARMD Jose Luis Rosales Meneses, MD, PhD
• Intravitreal Bevacizumab Therapy For Neovascular ARMD: A Pilot Study Virgilio Morales-Canton, MD
• Agreement among Canadian Retina Specialists In The Determination Of Treatment Eligibility For PDT In ARMD Rajeev Hemant Muni, MD
• The Role of Hyperthermia in Control of Sufoveal CNV: Stabilization of CNV With Low Recurrent Rate Masood Naseripour, MD
• Novel Macular Photorecovery Timer Detected Early Wet ARMD Changes David A. Newsome, MD
• Quality of Life in Patients with ARMD: Results from the V.I.S.I.O.N. Trial Manjula Patel, MD
• The Relationship Between Cataract Surgery, ARMD and PDT Ayala Pollack, MD
• Recurrence of CNV 18 months after PDT with or without Kenalog in ARMD Michael J. Potter, MD
• Vision-Specific Quality of Life at 12 Months in Subjects with or without Classic CNV due to ARMD: Phase III Clinical Trial of Ranibizumab (Lucentis) Carl Regillo, MD
• The Effect of Blue Light on Vascular Endothelial Growth Factor Kourous A. Rezai, MD
• Thermal Laser Photocoagulation Combined with IVT Injection for Treatment of CNV Edwin H. Ryan, MD
• Triple Therapy: PDT, Intravitreal Bevacizumab and Preservative Free Triamcinolone Acetonide for the Treatment of Exudative ARMD Arturo Santos, MD, PhD
• Avastin Adjuvants in CNV Surgery Joerg C. Schmidt, MD
• The PHP-II (Automated Preferential Hyperacuity Perimeter) For Detection of CNV in ARMD Ruth Axer Siegel, MD
• Effect on High Contrast Discriminated Target Central Fields of PDT with Vertporphyrin for CNVM due to ARMD Stephen H. Sinclair, MD
• Hypericin–Enhanced Argon Laser Photocoagulation for Subfoveal CNV Membrane in ARMD GŸngšr Sobaci, MD
• Intravitreal combination of Kenacort and Avastin (Ken-Av) for CNV ARMD Panos Stergiou
• The Relative Systemic Safety of Differing ARMD Therapies Ivan J Suner, MD
• Expression of VEGF and PEDF in CNV Membranes following Verteporfin PDT Olcay Tatar, MD
• Combination Therapy of PDT with Verteporfin and Intravitreal Pegaptanib in the Management of Exudative ARMD Asheesh Tewari, MD
• Suspension Phase Microsphere Immunoassay of Bevacizumab Levels in Ocular Fluids and Sera Susan J Wong, PhD
• Autologous Iris Pigment Epithelium Cell Transplantation for treatment of Dry MD: 2-year follow-up Narendra Armogan, MD, FRCS(C)
• Avastin—It’s Not Just for Retina Anymore Michael A. Singer, MD
• Treatment of Macular Hematoma due to ARMD by Displacement with Vitrectomy and Gas Injection Jean-François Le Rouic, MD
• Tritherapy using Avastin, Visudyne and Triamcinolone as Treatment of Neovascular ARMD Guy L’Helgoual’ch